Implantable Cardioverter Defibrillators (Cardiovascular) – Global Market Analysis and Forecast Model (COVID-19 Market Impact)

The model discusses in detail the impact of COVID-19 on Implantable Cardioverter Defibrillators market for the year 2020 and beyond. Cardiac Arrest or Sudden Cardiac Arrest (SCA) is a condition in which abnormal rhythms like Ventricular Fibrillation and Ventricular Tachycardia prevents the heart from pumping blood to the vital organs of the body. The only treatment of cardiac arrest is to defibrillate the heart to restore heart function which can be done using an external defibrillator; however, the chances of surviving an out of hospital cardiac arrest are thin. For patients with high risk of SCA, such as those with coronary artery disease or cardiomyopathy, a physician may prescribe anti-arrhythmic medication or an Implantable Cardioverter Defibrillator. The original implantable cardioverter-defibrillator was designed to detect only ventricular fibrillation and not for ventricular tachycardia. ICDs are used to record the heart's activity and treat dangerous ventricular arrhythmias with an electrical shock or pulse to the heart.


Who should buy this report?

This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for –

– CMO executives who must have deep understanding of the Implantable Cardioverter Defibrillators marketplace to make strategic planning and investment decisions.

– Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.

– Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Key Highlights

Competitive Assessment

Currently marketed Implantable Cardioverter Defibrillators and evolving competitive landscape:

– Insightful review of the key industry trends.

– Annualized total Implantable Cardioverter Defibrillators market revenue by segment and market outlooks from 2015-2030.

– Granular data on total procedures, units, average selling prices and market values by segment.

Reasons to buy

The model will enable you to:

– Understand the impact of COVID-19 on Implantable Cardioverter Defibrillators market.

– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

– Develop business strategies by understanding the trends shaping and driving Implantable Cardioverter Defibrillators market.

– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Implantable Cardioverter Defibrillators market in the future.

– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.

– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

– Track device sales in the global and country-specific Implantable Cardioverter Defibrillators market from 2015-2030.

– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies mentioned

Medtronic plc

Abbott Laboratories

Boston Scientific Corp

Biotronik SE & Co KG

MicroPort Scientific Corp



Discounts available for multiple purchases.
+44 20 7947 2745

Join our mailing list

Saved reports